Merck to lay off thousands more by 2015 | McClatchy Washington Bureau

×
Sign In
Sign In
    • Customer Service
    • Mobile & Apps
    • Contact Us
    • Newsletters
    • Subscriber Services

    • All White House
    • Russia
    • All Congress
    • Budget
    • All Justice
    • Supreme Court
    • DOJ
    • Criminal Justice
    • All Elections
    • Campaigns
    • Midterms
    • The Influencer Series
    • All Policy
    • National Security
    • Guantanamo
    • Environment
    • Climate
    • Energy
    • Water Rights
    • Guns
    • Poverty
    • Health Care
    • Immigration
    • Trade
    • Civil Rights
    • Agriculture
    • Technology
    • Cybersecurity
    • All Nation & World
    • National
    • Regional
    • The East
    • The West
    • The Midwest
    • The South
    • World
    • Diplomacy
    • Latin America
    • Investigations
  • Podcasts
    • All Opinion
    • Political Cartoons

  • Our Newsrooms

You have viewed all your free articles this month

Subscribe

Or subscribe with your Google account and let Google manage your subscription.

Economy

Merck to lay off thousands more by 2015

Alan M. Wolf - Raleigh News & Observer

July 29, 2011 03:55 PM

Merck plans to slash up to 13,000 more jobs by 2015, the latest large pharmaceutical corporation seeking to offset slowing sales by cutting costs.

Merck expects to continue hiring in growth areas of its business, including emerging markets. The company also will stick with expansion plans at its massive Durham operations, which packages and eventually will grow vaccines to protect against chicken pox and other diseases.

Officials expect to hire more than 150 people at that campus this year, adding to the 450 jobs created during the past few years.

Merck also continues to expand a packaging facility in Wilson that employs about 350 people.

Company spokesman David Caouette told the Associated Press that 35 percent to 40 percent of the new job cuts will be in the U.S., but that he couldn't provide specifics.

The cost-cutting news follows a similar strategy at other big drug makers, including Pfizer and GlaxoSmithKline. Faced with increasing generic competition and lower reimbursements from government health programs, the companies are reducing expenses, pushing harder to find promising new drugs and fine-tuning their business to appease investors.

Read the complete story at newsobserver.com

Read Next

Video media Created with Sketch.

Policy

Are Muslim-owned accounts being singled out by big banks ?

By Kevin G. Hall and

Rob Wile

December 17, 2018 07:00 AM

Despite outcry several years ago, U.S. banks are back in the spotlight as more Muslim customers say they’ve had accounts frozen and/or closed with no explanation given. Is it discrimination or bank prudence?

KEEP READING

MORE ECONOMY

National

The lights are back on, but after $3.2B will Puerto Rico’s grid survive another storm?

September 20, 2018 07:00 AM

Investigations

Title-pawn shops ‘keep poor people poor.’ Who’s protecting Georgians from debt traps?

September 20, 2018 12:05 PM

Agriculture

Citrus disease could kill California industry if Congress slows research, growers warn

September 11, 2018 03:01 AM

Politics & Government

The GOP’s new attack: Democrats wants to ‘end’ Medicare

September 07, 2018 05:00 AM

Economy

KS congressman: Farmers are ‘such great patriots’ they’ll ride out Trump trade woes

August 30, 2018 02:17 PM

Midterms

Democrats’ fall strategy: Stop talking Trump

August 24, 2018 05:00 AM
Take Us With You

Real-time updates and all local stories you want right in the palm of your hand.

McClatchy Washington Bureau App

View Newsletters

Subscriptions
  • Newsletters
Learn More
  • Customer Service
  • Securely Share News Tips
  • Contact Us
Advertising
  • Advertise With Us
Copyright
Privacy Policy
Terms of Service